PTEN and prostate carcinoma: Using a panel of human prostate cancer cell lines (PC3, LNCaP, and DU145) and mouse prostate cancer cells derived from the adenocarcinoma of PTEN null mice (PTEN-CaP8), Narayanan et al. [17] first reported the significant proliferation inhibitory effects of gnetin C in cancer cells without affecting normal prostate epithelial RWPE-1 cells.